Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above

Desmond Curran, Ruprecht Schmidt‐Ott, Ulf Schutter, +3

BMC Infectious Diseases

Impact of Herpes Zoster and Post-Herpetic Neuralgia on Health-Related Quality of Life in Japanese Adults Aged 60 Years or Older: Results from a Prospective, Observational Cohort Study

Akiko Mizukami, Keiko Sato, Koichi Adachi, +5

Clinical Drug Investigation

Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older

Desmond Curran, Lidia Oostvogels, Thomas C. Heineman, +15

The Journals of Gerontology Series A

Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals

Desmond Curran, Joon H. Kim, Sean Matthews, +9

Journal of the American Geriatrics Society

Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged ≥50 years: A prospective study

Ruprecht Schmidt‐Ott, Ulf Schutter, Jörg Simon, +8

Journal of Infection

Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT)

Desmond Curran, Sean Matthews, Scott D. Rowley, +23

Biology of Blood and Marrow Transplantation

Economic Burden and Impact on Quality of Life of Herpes Zoster in Spanish Adults Aged 50 Years or Older: A Prospective Cohort Study

Javier Díez‐Domingo, Desmond Curran, María del Rosario Cambronero, +2

Advances in Therapy

The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial

Kenneth E. Schmader, Myron J. Levin, Katrijn Grupping, +12

The Journals of Gerontology Series A

The Economic Burden and Impact on Quality of Life of Herpes Zoster and Postherpetic Neuralgia in Individuals Aged 50 Years or Older in Italy

Sean Matthews, Antonio María, Marco Passamonti, +4

Open Forum Infectious Diseases

The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus‐associated disease in breakthrough infections in adults ≥60 years of age

Desmond Curran, Sean Matthews, Eliazar Sabater Cabrera, +14

Influenza and Other Respiratory Viruses